Adolescent girls and young women in sub-Saharan Africa remain disproportionately affected by HIV. Dr. Sehulong Robert Moraba worked to expand prevention tools for this group as a Sub-Investigator in the Phase 3 GS-US-412-5624 trial. This study evaluated the safety and efficacy of once-daily F/TAF (Descovy) for Pre-Exposure Prophylaxis (PrEP).
The trial (SAHPRA ref: 20210301) provided vital evidence on the use of this alternative antiretroviral regimen for HIV prevention in cisgender women at risk. Dr. Moraba’s contribution helped ensure the study’s rigorous conduct in a real-world population, informing guidelines and access to more PrEP choices.
